BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
As a few export orders of subsidiaries spilled over to the next quarter, Aarti Drugs Ltd.’s Q4 FY21 was below expectation.
Sales grew 11.6% YoY to Rs 5 billion.
Growth was driven by formulations (up 22.1% YoY) and specialty chemicals (89%).
The gross margin contracted 72 basis points to 36.3% due to lower share of exports and higher raw material cost.
The Ebitda margin, though, expanded slightly (27 basis points) to 16.1% due to curtailed overheads.
Through better utilisation of capacities and additions, the company is on track to deliver 18% revenue growth in the next four to five years.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.